| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Recursion Pharmaceuticals, Inc.$3.56
-0.2 (-5.32%)
C 51Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.60 B
EPS
-1.20
P/E Ratio
-
Value Trade
63.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.47 M
R&D Expenses
87.90 M
Operating CF
-81.10 M
Total Assets
1.34 B
Total Liabilities
314.75 M
Equity
1.02 B
D/E Ratio
12,345
0.33 %
Week
-16.85 %
1 Month
-17.31 %
3 Month
-23.02 %
6 Month
-87.08 %
5 Year
-89.97 %
All Time
Cash Data
Cash Position
654.47 M
Monthly Burn
27.03 M
Runway
22 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
20.81 M
52 Week Range
2.77 - 7.18
% held by Insiders
11.35 %
% held by Institutions
59.19 %
Enterprise Value
1.01 B
Total Shares
522.08 M
Short %
42.04 %
Float Shares
409.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Recursion Pharmaceuticals, Inc.
319Total events
17Upcoming
80Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 17
Aug 2026
T2Milestone Payment
Potential $200 million in milestone payments over next 2 years from partnerships
Q1 2027
T2Timing Guidance
Early Phase 1 safety and PK combination data for REC-617 (CDK7) expected in 1H27
Q1 2027
T2Timing Guidance
Early Phase 1 safety and PK monotherapy data for REC-3565 (MALT1) expected in 1H27
Q2 2027
T2Timing Guidance
Early Phase 1 safety and PK monotherapy data for REC-4539 (LSD1) expected in 2H27
May 2027
T2Timing Guidance
Partnered discovery milestones: development candidate designation and target validation milestones over next 12 months
TBD
T3Enrollment Update
Plan to expand population from ≥55 to ≥18 years old and optimize dosing schedule
TBD
T2Milestone Payment
Rallybio eligible for $12.5M contingent equity payment upon initiation of additional preclinical studies
Event history 302
May 6, 2026
Apr 6, 2026
◆Management ChangeCorporate
Vicki Goodman, M.D. appointed as Chief Medical Officer effective April 6, 2026
Q2 2026
◆Trial InitiationREV102Trial
Initiation of Phase 1 clinical trials expected in H2 2026
hypophosphatasiasource ↗
Q2 2026
◆Milestone PaymentREV102Corporate
Rallybio eligible for $5M milestone payment upon initiation of dosing in Phase 1 study
hypophosphatasiasource ↗
Apr 2026
▲First Patient DosedREC-4539Trial
First patient dosed in Phase 1 ENLYGHT study of REC-4539 (LSD1 inhibitor) in solid tumors
solid tumors, including small cell lung cancer (SCLC)source ↗
Q2 2026
◆Timing GuidanceREC-4881Presentation
Regulatory update on registrational pathway for REC-4881 expected in 2H26
familial adenomatous polyposis (FAP)source ↗
Q2 2026
◆Timing GuidanceREC-1245Presentation
Additional Phase 1 dose escalation data expected in 2H26 (duplicate)
solid tumorssource ↗
Q2 2026
◆Timing GuidanceREC-7735Presentation
Go/no-go decision on Phase 1 initiation for REC-7735 (PI3Kα H1047R) expected in 2H26
Q2 2026
◆Timing GuidanceREC-102Presentation
Go/no-go decision on Phase 1 initiation expected in 2H26 (duplicate)
Q2 2026
◆Topline ReadoutREC-3565Clinical Data
Early Phase 1 safety and PK monotherapy data for REC-3565 expected
B cell malignanciessource ↗
Mar 31, 2026
▲Partnership / LicenseCorporate
Expanded strategic partnership with Citeline to advance AI-enabled ClinTech platform
Mar 16, 2026
Drug Pipeline Intelligence
C51
Pipeline Score $760M
Pipeline ValueOvervalued
Valuation Signal7
Drugs Scored0.5x
rNPV / MCap Top 76%
Micro Cap (rank 220 of 912)
Percentile RankRecursion Pharmaceuticals, Inc. carries a moderate pipeline score (51/100), with $1.9B risk-adjusted pipeline value, led by EXS21546 for in Oncology (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXS21546 for Small molecule | Oncology | Phase 1 | NCT04727138 | 10% | $1.2B | COMPLETED | 64 | - | - | May 12, 2022 | - | May 16, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
REC-1245 | solid tumors | Phase 1/2 | 2026-05-06 | REC-1245 was well-tolerated across select solid tumors(n=16); No dose-limiting toxicities (DLTs) have been observed to date; the maximum tolerated dose has not yet been reached; The majority of TRAEs were Grade 1 or 2; most common GI-related events were constipation, nausea, and vomiting; Pharmacokinetic analysis demonstrates predictable, dose-dependent exposure across evaluated patients Read More | Recursion Reports First Quarter Financial Results and Provides Business Update Read More | |
REC-1245 | solid tumors | Phase 1/2 | 2026-05-06 | REC-1245 was well-tolerated across select solid tumors(n=16); No dose-limiting toxicities (DLTs) have been observed to date; the maximum tolerated dose has not yet been reached; The majority of TRAEs were Grade 1 or 2; most common GI-related events were constipation, nausea, and vomiting; Pharmacokinetic analysis demonstrates predictable, dose-dependent exposure across evaluated patients Read More | Recursion Reports First Quarter Financial Results and Provides Business Update Read More | |
REC-1245 | solid tumors | Phase 1/2 | 2026-05-06 | REC-1245 was well-tolerated across select solid tumors(n=16); No dose-limiting toxicities (DLTs) have been observed to date; the maximum tolerated dose has not yet been reached; The majority of TRAEs were Grade 1 or 2; most common GI-related events were constipation, nausea, and vomiting; Pharmacokinetic analysis demonstrates predictable, dose-dependent exposure across evaluated patients Read More | Recursion Reports First Quarter Financial Results and Provides Business Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RXRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RXRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RXRXRecursion To Participate In Upcoming Investor Conferences
Recursion To Participate In Upcoming Investor Conferences
Read more →RXRXRecursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Read more →RXRXRecursion Reports First Quarter Financial Results and Provides Business Update
Recursion Pharmaceuticals (RXRX) reported strong progress in its clinical pipeline during Q1 2026, achieving key milestones across various programs. Notably, REC-1245 showed promising safety and pharmacokinetics in solid tumors, while REC-4881 exhibited significant efficacy in Phase 2 trials. The company continues to maintain a solid cash position, projecting operational sustainability into early 2028.
Read more →RXRXRecursion Announces Board Transition
Recursion has announced that Chris Gibson, Ph.D., will step down from the Board of Directors but will serve as an advisor. CEO Najat Khan emphasized the company's commitment to long-term value creation and expressed optimism about future developments. Recursion is focused on advancing its investigational medicines across various therapeutic areas using its AI-powered platform. The organization's infrastructure supports its mission to translate complex science into effective therapies.
Read more →RXRXRecursion To Report First Quarter 2026 Business Updates And Financial Results On May 6
Recursion To Report First Quarter 2026 Business Updates And Financial Results On May 6
Read more →RXRX▲ +8.1%on this news
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Recursion has announced an expansion of its strategic partnership with Citeline, aiming to enhance its AI-enabled ClinTech platform. This collaboration integrates Citeline’s real-world data capabilities, supporting more precise trial designs and improved decision-making in drug development. The CEO of Recursion noted that this partnership has already led to significant improvements in enrollment rates for clinical trials. The overall goal is to create a more connected and patient-centered biopharmaceutical ecosystem.
Read more →RXRXRecursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Recursion has appointed Dr. Vicki Goodman as its new Chief Medical Officer, effective April 6, 2026. She succeeds Dr. David Mauro, who has served in the role for three years. Dr. Goodman brings over two decades of experience in oncology and drug development, which is expected to significantly benefit Recursion's clinical programs and pipeline advancements.
Read more →RXRX▲ +6.8%on this news
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Recursion (NASDAQ: RXRX) reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical programs and partnerships. The company achieved over $500 million in milestone payments and reduced its cash operating expenses to approximately $400 million. CEO Najat Khan emphasized the maturity of their AI-driven drug discovery platform, which is expected to drive future growth.
Read more →RXRXRecursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
Recursion (RXRX) will participate in a Lightning Talk at the NVIDIA GTC AI Conference, showcasing advancements in AI and automation in drug discovery. CEO Ira Hoffman will discuss the collaboration with HighRes Biosolutions to develop self-driving labs. This initiative aims to revolutionize drug discovery processes through advanced technologies and massive data generation.
Read more →RXRXRecursion to Participate in Upcoming Investor Conferences
Recursion (RXRX) has announced its participation in upcoming investor conferences, showcasing its leadership in the TechBio sector. The company utilizes advanced technologies to decode biology and improve lives, leveraging a powerful platform and machine-learning algorithms. This initiative highlights Recursion's commitment to advancing medicine through innovative approaches.
Read more →RXRXRecursion To Report Fourth Quarter And Full Year 2025 Business Updates And Financial Results On February 25
Recursion To Report Fourth Quarter And Full Year 2025 Business Updates And Financial Results On February 25
Read more →RXRXRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion (NASDAQ: RXRX) announced the grant of inducement restricted stock unit awards for 820,431 shares to 17 new employees. This decision, made by the Compensation Committee, aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance talent acquisition. The awards will vest over time, contingent on continued employment.
Read more →RXRXRecursion To Present At 44th Annual J P Morgan Healthcare Conference
Recursion To Present At 44th Annual J P Morgan Healthcare Conference
Read more →RXRXPositive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Recursion announced positive Phase 1b/2 results from the TUPELO trial of REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial showed a median reduction of 43% in polyp burden after 12 weeks, with 82% of patients maintaining reductions at Week 25. This marks a significant advancement in treatment options for FAP, a condition with no approved therapies.
Read more →RXRX▼ -5.8%on this news
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
Recursion announced a webinar scheduled for December 8, 2025, to present new clinical data from the TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP). The webinar will focus on updated safety and efficacy results. This event will be streamed live on multiple platforms, showcasing Recursion's commitment to transparency in clinical research.
Read more →RXRXRecursion Reports Third Quarter 2025 Financial Results and Provides Business Update
Recursion reported its third quarter 2025 financial results, highlighting significant progress in its internal pipeline and strategic partnerships. The company achieved over $500 million in milestone payments from collaborations with Roche and Genentech. Recursion continues to advance its clinical programs and expects to leverage its AI-enabled platform to enhance drug discovery and development.
Read more →RXRXRecursion Announces CEO Transition Plan to Drive Next Phase of Growth
Recursion has announced a leadership transition plan, effective January 1, 2026, appointing Najat Khan as the new CEO. This decision aims to maintain continuity and drive the next phase of growth for the company. The current CEO, Chris Gibson, will become Chairman, ensuring his expertise remains integral to Recursion's evolution. Khan's leadership is expected to enhance the company's innovative approach in drug discovery.
Read more →RXRX▼ -6.2%on this news
Recursion To Report Third Quarter 2025 Business Updates And Financial Results On November 5th
Recursion To Report Third Quarter 2025 Business Updates And Financial Results On November 5th
Read more →RXRXRecursion Reports Second Quarter 2025 Financial Results and Provides Business Update Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for R
Recursion has reported its financial results for Q2 2025, highlighting a $7 million milestone from its partnership with Sanofi. The company provided updates on its clinical programs, including the potential first-in-class drugs REC-1245 and REC-617, which show early promise in treating cancer. The DAHLIA and ELUCIDATE trials are currently enrolling patients, focusing on specific tumor types and leveraging advanced AI-driven insights. Recursion's collaborative efforts with major pharmaceutical companies continue to expand its portfolio, indicating continued momentum in its drug development pipeline.
Read more →RXRX▼ -5.7%on this news
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Recursion (RXRX) will report its second quarter 2025 financial results on August 5, 2025, before market opening. The company will host a live earnings call at 8:00 am ET, allowing public participation through questions submitted online. Recursion continues to innovate in drug discovery using advanced technologies.
Read more →RXRX▲ +8.7%on this news
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion has acquired full rights to REV102, an ENPP1 inhibitor aimed at treating hypophosphatasia (HPP). This acquisition allows Recursion to expedite the development of a potential first oral disease-modifying therapy for HPP patients. The program, which leverages Recursion's AI platform, is currently in IND-enabling studies, with Phase 1 trials expected to start in late 2026.
Read more →RXRX▲ +8.7%on this newsshared move
Forward-Looking Statements This document contains information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, t
Recursion has acquired full rights to the ENPP1 inhibitor program (REV102) from Rallybio, which targets the treatment of hypophosphatasia (HPP). This acquisition may accelerate the development of what could become the first oral disease-modifying treatment for HPP. Leveraging its advanced AI and experimental platform, Recursion aims to optimize REV102 for better efficacy and patient access. However, the asset is currently in preclinical development, posing challenges related to future study outcomes and market entry.
Read more →RXRXCorporate Deck June 2025 Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may
Recursion Pharmaceuticals has outlined its strategic focus on employing technology to accelerate drug discovery processes. The company presented forward-looking statements about its ability to scale operations and prioritize high-potential drug programs, particularly in oncology and rare diseases. Additionally, Recursion is working on partnerships that could bring substantial financial returns, as indicated by the potential for billions in milestone payments. The presentation emphasizes the company's capabilities and ambition to improve patient treatment outcomes through innovative approaches.
Read more →RXRX▲ +11.8%on this newsshared move
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
MIT and Recursion have launched Boltz-2, an advanced AI model designed to predict biomolecular binding affinities with unprecedented speed and accuracy. This open-source model significantly reduces the time and cost associated with drug discovery, allowing researchers to focus on promising compounds more effectively. Boltz-2's capabilities position it as a leading tool in the field, surpassing previous models.
Read more →RXRX▼ -16.6%on this news· ran to -27% by day 1shared move
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update Pipeline Delivered on our commitment to a more focused R D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical
Recursion announced its financial results for the first quarter of 2025, highlighting progress in its streamlined R&D strategy with over five clinical and preclinical programs. The company reached a significant milestone in its collaboration with Sanofi, generating a $7 million payment. Preliminary data from the REC-4881 study showed a median 43% reduction in polyp burden for familial adenomatous polyposis. However, the company also announced the discontinuation of several programs due to insufficient clinical activity.
Read more →RXRXRecursion To Report First Quarter 2025 Business Updates And Financial Results On May 5th
Recursion To Report First Quarter 2025 Business Updates And Financial Results On May 5th
Read more →RXRXRecursion To Present Preliminary Clinical Data From The Ongoing Phase 1b 2 Trial Of Rec 4881 In Fap At Digestive Disease Week 2025
Recursion To Present Preliminary Clinical Data From The Ongoing Phase 1b 2 Trial Of Rec 4881 In Fap At Digestive Disease Week 2025
Read more →RXRX▲ +17.1%on this news· ran to +39% by day 3
Recursion And Enamine Release New Ai Enabled Targeted Compound Libraries
Recursion And Enamine Release New Ai Enabled Targeted Compound Libraries
Read more →RXRX▼ -5.5%on this news· ran to +37% by day 3shared move
Recursion Announces First Patient Dosed In Phase 1 Clinical Study Of Rec 3565 A Selective Malt1 Inhibitor For Relapsed Or Refractory B Cell Lymphomas
Recursion Announces First Patient Dosed In Phase 1 Clinical Study Of Rec 3565 A Selective Malt1 Inhibitor For Relapsed Or Refractory B Cell Lymphomas
Read more →RXRXRecursion To Participate In Upcoming Investor Conference
Recursion To Participate In Upcoming Investor Conference
Read more →RXRX▼ -6.6%on this news
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandj Bumpus and Mammoth Biosciences COO and CFO Elaine Sun Dr. Bumpus brings deep experience in scientific innovation and regulat
Recursion has appointed Dr. Namandj Bumpus and Elaine Sun to its Board of Directors, effective March 15. Dr. Bumpus, a former FDA Principal Deputy Commissioner, brings extensive experience in scientific innovation and regulatory frameworks. Elaine Sun, the COO and CFO at Mammoth Biosciences, adds robust financial and corporate strategy expertise. These appointments are expected to bolster Recursion's strategic leadership as it continues to expand its clinical pipeline and platform.
Read more →RXRXRecursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints
Recursion (RXRX) reported its fourth-quarter and fiscal year 2024 business updates, showcasing positive developments in its pipeline, including promising efficacy data for REC-617 and REC-994. The company advanced three new clinical studies, emphasizing its commitment to oncology and rare diseases. Additionally, Recursion completed a significant business combination with Exscientia and generated substantial cash inflows from various partnerships. The CEO highlighted the company's potential to drive faster drug development and improve patient outcomes through its innovative platform.
Read more →RXRXRecursion To Report Fourth Quarter And Fiscal Year 2024 Business Updates And Financial Results On February 28th
Recursion To Report Fourth Quarter And Fiscal Year 2024 Business Updates And Financial Results On February 28th
Read more →RXRXAltitude Lab Launches Pre Seed Venture Fund Anchored By Recursion Ceo Chris Gibson Enabling Sbir Awarded Biotechs Hit By Funding Gap To Build In Salt Lake City
Altitude Lab Launches Pre Seed Venture Fund Anchored By Recursion Ceo Chris Gibson Enabling Sbir Awarded Biotechs Hit By Funding Gap To Build In Salt Lake City
Read more →RXRXAltitude Lab Startups Raise 154m In Capital
Altitude Lab Startups Raise 154m In Capital
Read more →RXRXRecursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Recursion presented positive Phase 2 results for REC-994 in treating Cerebral Cavernous Malformations (CCM) at the International Stroke Conference. The SYCAMORE study met its primary safety endpoint without significant adverse effects, showing promising signals for lesion volume reduction and improved patient outcomes. Notably, 50% of participants treated with 400 mg of REC-994 experienced reduced lesion volume after 12 months. The company plans to discuss next steps with regulatory authorities and continue ongoing studies to further investigate REC-994's efficacy.
Read more →RXRX▼ -5.8%on this news
Recursion Announces Two Key Investigational Oncology Drugs Advancing To Clinical Trials Targeting High Unmet Needs In Hematologic Malignancies Small Cell Lung Cancer More
Recursion Announces Two Key Investigational Oncology Drugs Advancing To Clinical Trials Targeting High Unmet Needs In Hematologic Malignancies Small Cell Lung Cancer More
Read more →RXRXRecursion To Present At 43rd Annual Jp Morgan Healthcare Conference
Recursion To Present At 43rd Annual Jp Morgan Healthcare Conference
Read more →RXRXRecursion Pharmaceuticals Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Recursion Pharmaceuticals Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Read more →RXRXRecursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Recursion Pharmaceuticals has released initial clinical data for REC-617, a CDK7 inhibitor, showing promising results from a Phase 1/2 dose-escalation study. A confirmed partial response was noted in a heavily pre-treated patient with platinum-resistant ovarian cancer, with additional patients achieving stable disease. The therapy exhibited a favorable safety profile, with no significant treatment-related discontinuations reported. The study continues, with plans to expand into combination treatments in the near future.
Read more →RXRX▼ -6.5%on this news
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion Pharmaceuticals has initiated a Phase 1/2 clinical trial for REC-1245, a new therapeutic agent targeting biomarker-enriched solid tumors and lymphoma. The dosing of the first patient marks a significant milestone in the development of this potential first-in-class RBM39 degrader. With preclinical data indicating that REC-1245 may disrupt DNA damage response networks, the therapy aims to address an initially estimated population of over 100,000 patients in the US and EU5. The trial will assess safety, tolerability, and preliminary activity as part of its objectives.
Read more →RXRXRecursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion has completed its business combination with Exscientia, effectively making Exscientia a wholly owned subsidiary. This merger is aimed at enhancing a technology-enabled drug discovery platform by integrating their expertise and resources. The combined entity boasts more than 10 clinical and preclinical programs, with substantial financial backing from partnerships. The leadership structure has been updated to reflect the new organization, and both companies are poised for growth in the AI-driven drug development space.
Read more →RXRXclosingdeck NOVEMBER 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are n
Recursion Pharmaceuticals has shared a presentation detailing its future plans, including advancements in drug discovery and the potential for significant revenue from upcoming projects and collaborations. The company anticipates major milestones across multiple clinical programs, with a particular focus on transformative therapies for oncology and rare diseases. Forward-looking statements regarding the integration of its business with Exscientia and the impact of various market factors were also highlighted, suggesting a cautious outlook despite optimism about potential outcomes.
Read more →RXRXRecursion And Exscientia Shareholders Approve The Proposed Combination
Recursion And Exscientia Shareholders Approve The Proposed Combination
Read more →RXRXRecursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
Recursion has announced the launch of OpenPhenom-S/16, a foundation model for microscopy data, now available on Google Cloud's Vertex AI Model Garden. This model aims to replace traditional microscopy analysis pipelines, significantly improving the recall of known biological relationships, thus facilitating faster and more effective drug discovery processes. The initiative reflects Recursion's commitment to enhance research capabilities in life sciences and supports non-commercial researchers with an advanced tool. Accompanying data releases, including the RxRx3-core dataset, reinforce their dedication to accelerating biomedical research.
Read more →RXRXRecursion Provides Business Updates and Reports Third Quarter 2024 Financial Results Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dose
Recursion Pharmaceuticals reported several significant milestones in their third quarter 2024 financial results, including encouraging data from a Phase 2 trial in Cerebral Cavernous Malformation and the first patient dosed in a Phase 2 trial for recurrent C. difficile infection. Notably, the company secured a $30 million option from Roche-Genentech, with potential total payments exceeding $500 million. Additionally, Recursion entered an expanded collaboration with Google Cloud to further develop its drug discovery platform. Despite the positive developments, the company reported an increased net loss of $95.8 million compared to the previous year.
Read more →RXRXRecursion To Report Third Quarter 2024 Business Updates And Financial Results On November 6th
Recursion To Report Third Quarter 2024 Business Updates And Financial Results On November 6th
Read more →RXRXRecursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Recursion has announced the dosing of its first patient in a Phase 2 clinical trial for REC-3964, a new non-antibiotic treatment for recurrent Clostridioides difficile infection. The drug acts by blocking the catalytic activity of the toxin's glucosyltransferase, offering a potential novel approach without disturbing the gut microbiome. The trial aims to assess the safety and efficacy of REC-3964, with initial data suggesting its superiority over existing treatments in preclinical models. This advancement highlights Recursion's commitment to addressing a significant public health challenge posed by recurrent C. difficile infections.
Read more →RXRXRecursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma First program to combine Recursion's end-
Recursion has announced the FDA's clearance of its investigational new drug application for REC-1245, a potential first-in-class RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. This development is significant as it reflects the rapid progress from drug discovery to clinical trial initiation, achieved through Recursion's AI-enabled platform. The Phase 1 clinical trial is set to commence in Q4 2024, targeting a patient population estimated at 100,000 in the US and EU. Preclinical data supports REC-1245's ability to induce therapeutic effects by degrading RBM39, thus offering new opportunities for treatment.
Read more →RXRX▼ -16.6%on this news
rxrxsept2024 September 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are
Recursion Pharmaceuticals, Inc. has presented forward-looking statements that focus on their strategies to advance clinical studies, specifically highlighting the SYCAMORE trial data and potential therapeutic developments. The company anticipates significant milestones, including an upcoming meeting with the FDA and a joint business combination with Exscientia. However, the merger presents multiple risks and uncertainties related to regulatory approvals, operational integration, and retention of personnel. Overall, Recursion aims to improve the efficiency and efficacy of drug development and bring transformative therapies to market.
Read more →RXRX▼ -16.6%on this news
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
Recursion announced positive results from the Phase 2 SYCAMORE trial of REC-994 for symptomatic Cerebral Cavernous Malformation (CCM), meeting its primary safety endpoint. The study showed similar adverse event profiles across dosage arms and suggested a trend towards efficacy in reducing lesion size at higher doses. However, no significant improvements in patient-reported outcomes were observed at the 12-month mark. The company plans to discuss next steps with the FDA and present the findings at a medical conference, emphasizing the need for further studies.
Read more →RXRXRecursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities Brings together Recursion s scaled biology exploration and translational capabi
Recursion and Exscientia announced a definitive agreement to merge, enhancing their capabilities in drug discovery and development. This combination is designed to industrialize the drug discovery process, leveraging advanced technologies and maximizing efficiency. The transaction, subject to shareholder and regulatory approvals, aims to create a leader in precision medicine. It is anticipated to yield significant revenue growth and increase the speed of delivering effective drugs to patients.
Read more →RXRXRecursion Updates L Earnings Call On August 8th To 8 30 Am Et 6 30 Am Mt
Recursion Updates L Earnings Call On August 8th To 8 30 Am Et 6 30 Am Mt
Read more →RXRXRecursion Provides Business Updates And Reports Second Quarter 2024 Financial Results
Recursion Provides Business Updates And Reports Second Quarter 2024 Financial Results
Read more →RXRXCorrection Recursion Provides Business Updates And Reports Second Quarter 2024 Financial Results
Correction Recursion Provides Business Updates And Reports Second Quarter 2024 Financial Results
Read more →RXRXRecursion To Report Second Quarter 2024 Business Updates And Financial Results On August 8th
Recursion To Report Second Quarter 2024 Business Updates And Financial Results On August 8th
Read more →RXRX▼ -13.5%on this news
Recursion Announces Pricing Of 200 Million Public Offering Of Class A Common Stock
Recursion Announces Pricing Of 200 Million Public Offering Of Class A Common Stock
Read more →RXRX▼ -6.6%on this news· ran to -20% by day 3shared move
Recursion Announces Proposed Offering of Class A Common Stock
Recursion Pharmaceuticals, Inc. announced a proposed public offering of $200 million in Class A common stock. All shares offered are from Recursion itself, with underwriters having the option to purchase an additional 15%. The offering depends on market conditions and other variables, with no guarantees regarding completion. Goldman Sachs and J.P. Morgan are leading the underwriting process. The offering aims to support Recursion’s drug discovery initiatives leveraging advanced technologies and a proprietary dataset.
Read more →RXRX▲ +5.5%on this newsshared move
Recursion Gives Guidance on Seven Clinical Readouts within 18 Months and Partnership Updates at Its Download Day Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which i
Recursion has updated investors on its pipeline, announcing seven clinical trial readouts anticipated within 18 months. The company also revealed its partnership with Bayer, which will involve delivering multi-modal data packages and developing a joint oncology project. Prominent speakers, such as NVIDIA's CEO, will feature in the upcoming Download Day event, highlighting Recursion's commitment to leveraging AI and machine learning in drug discovery. While there are promising advancements, Recursion faces inherent challenges related to regulatory approvals and competition in the biopharma sector.
Read more →RXRXPower Of Recursion Os On Display At Genome Scale In Nature Genetics Paper Detailing Potential Limitation Of Crispr Gene Editing Tool
Power Of Recursion Os On Display At Genome Scale In Nature Genetics Paper Detailing Potential Limitation Of Crispr Gene Editing Tool
Read more →RXRXRecursion Appoints Robert Hershberg M D Ph D As New Chair Of The Board
Recursion Appoints Robert Hershberg M D Ph D As New Chair Of The Board
Read more →RXRX▲ +10.2%on this news
Recursion Announces Completion Of Nvidia Powered Biohive 2 The Largest Supercomputer In Pharmaceutical Industry
Recursion Announces Completion Of Nvidia Powered Biohive 2 The Largest Supercomputer In Pharmaceutical Industry
Read more →RXRXRecursion Provides Business Updates and Reports First Quarter 2024 Financial Results On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024 Performance benchmarking completed o
Recursion has reported positive business updates along with its first-quarter 2024 financial results. The company is on track to begin reading out data from multiple Phase 2 clinical trials starting in Q3 2024. They have completed performance benchmarking on BioHive-2, a next-generation supercomputer, and they continue to expand their transcriptomics capabilities. Additionally, a partnership agreement with Helix enhances their access to vital real-world patient data, which will support their ongoing and future research initiatives.
Read more →RXRX▲ +5.4%on this news
Recursion To Report First Quarter 2024 Business Updates And Financial Results On May 9
Recursion To Report First Quarter 2024 Business Updates And Financial Results On May 9
Read more →RXRXAltitude Lab Secures Small Business Administration Growth Fund Accelerator Grant To Launch Horizon A Commercialization Partnering Program
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant To Launch Horizon A Commercialization Partnering Program
Read more →RXRXRecursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Recursion has appointed Dr. Najat Khan as its Chief R&D Officer and Chief Commercial Officer, bringing her extensive experience in drug discovery and data science. Dr. Khan's leadership is expected to enhance Recursion's research capabilities and commercial strategies. She has previously worked with Johnson & Johnson and has a strong background in biological, chemical, and medical sciences. This appointment comes at a time when Recursion looks to pioneer advancements in the TechBio sector.
Read more →RXRXRecursion Publishes Annual Environmental Social And Governance Report
Recursion Publishes Annual Environmental Social And Governance Report
Read more →RXRX▼ -7.3%on this news
Recursion Announces Plans to Open New Office in London
Recursion has announced plans to open a new office in London's King's Cross neighborhood, set to open in June 2024. This expansion aims to tap into Europe's growing TechBio talent pool and innovation ecosystem. The office will house Recursion and Valence Labs, alongside plans to hire new staff to support their operations. Furthermore, the building is designed to be environmentally sustainable, featuring net-zero carbon emissions and various employee amenities.
Read more →RXRXRecursion Hosts Second Annual Rare Disease Day Events For Utah S Rare Disease Community
Recursion Hosts Second Annual Rare Disease Day Events For Utah S Rare Disease Community
Read more →RXRX▲ +5.1%on this newsshared move
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results Multiple clinical programs from Recursion's first generation platform are on track to read out Phase 2 data in H2 2024
Recursion provided a business update and announced its financial results for the fourth quarter and fiscal year 2023, highlighting significant progress across several clinical programs. The company is set for Phase 2 data readouts in multiple trials from late 2024 through early 2025 and has integrated casual AI models in collaboration with Tempus. They have also in-licensed a novel treatment for fibrotic diseases, which is entering IND-enabling studies. Overall, Recursion is poised for future milestones while also facing the ongoing challenges of maintaining innovation in the evolving TechBio sector.
Read more →RXRXRecursion To Host Public L Earnings Call On February 27
Recursion To Host Public L Earnings Call On February 27
Read more →RXRXAltitude Lab Startups Raise Over 120m In Capital
Altitude Lab Startups Raise Over 120m In Capital
Read more →RXRX▲ +5.7%on this news
Recursion Unveils Lowe Drug Discovery Software At The J P Morgan Healthcare Conference
Recursion Unveils Lowe Drug Discovery Software At The J P Morgan Healthcare Conference
Read more →RXRX▲ +14.7%on this news· ran to +38% by day 3shared move
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Recursion (NASDAQ: RXRX) has announced the in-licensing of a new chemical entity from Bayer AG aimed at treating fibrotic diseases. This compound showcases promising early data, suggesting it could reverse fibrotic processes. Recursion's unique technology platform and collaboration with Bayer are expected to accelerate the advancements in this area of drug discovery. The company's ongoing research emphasizes its commitment to addressing complex disease biology.
Read more →RXRXRecursion To Present At The 42nd Annual J P Morgan Healthcare Conference On January 8
Recursion To Present At The 42nd Annual J P Morgan Healthcare Conference On January 8
Read more →RXRX▼ -5.8%on this news
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space pr
Recursion has announced a new partnership with Enamine aimed at generating enriched compound libraries for drug discovery. Utilizing Recursion's MatchMaker tool, the collaboration will identify compounds that bind to key biological targets from Enamine's extensive collection of 36 billion compounds. The agreement includes significant benefits for Recursion, such as access to unique data and preferential pricing on libraries. The partnership highlights advancements in drug discovery through the integration of machine learning and vast chemical data.
Read more →RXRX▼ -7.1%on this news
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
Recursion has announced a collaboration with Tempus Labs to access over 20 petabytes of patient-centric oncology data, which will support the development of biomarker-based therapeutics. The company is also significantly enhancing its supercomputing capabilities with NVIDIA to potentially rank among the top 50 supercomputers globally. Additionally, Recursion has updated its partnership with Bayer, allowing for up to seven new oncology programs, with the possibility of receiving $1.5 billion in success-based payments.
Read more →RXRX▼ -7.1%on this news
Bayer And Recursion Focus Research Collaboration On Oncology
Bayer And Recursion Focus Research Collaboration On Oncology
Read more →RXRX▼ -7.1%on this news
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of tr
Recursion has announced key business developments and financial results for Q3 2023, including a collaboration with Tempus that grants access to a vast database for enhancing AI model training in oncology. The company is expanding its supercomputer capabilities to support advanced data analysis with plans to become one of the world's top supercomputers. Additionally, Recursion's collaborations with Bayer and Roche are evolving, reflecting growing recognition of its technology in the biopharma space. The ongoing clinical trials for various drug candidates also indicate a robust pipeline aimed at addressing significant medical needs.
Read more →RXRXRecursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events Recursion to explore init
Recursion has completed a Phase 1 study for its drug REC-3964, aimed at treating Clostridioides difficile infection. The study demonstrated a strong safety and tolerability profile, with no serious adverse events reported among healthy volunteers. Encouraged by these results, the company is planning to initiate a Phase 2 proof-of-concept study in patients with recurrent infections in 2024. This marks a significant step forward in the development of this novel therapeutic approach.
Read more →RXRXRecursion Bridges The Protein And Chemical Space With Massive Protein Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion Bridges The Protein And Chemical Space With Massive Protein Ligand Interaction Predictions Spanning 36 Billion Compounds
Read more →RXRXRecursion Provides Business Updates and Reports Second Quarter 2023 Financial Results Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billi
Recursion reported its second quarter 2023 financial results and highlighted significant advancements in drug discovery technologies, particularly through a partnership with NVIDIA. The company is focused on developing large-scale foundation models and digital chemistry technologies to predict ligand-protein interactions. Notable clinical trials for various drug candidates are ongoing, with data readouts expected in the near future. Recent acquisitions and partnerships are expected to bolster the company's capabilities in AI and drug development.
Read more →RXRX▼ -7%on this news
Recursion Launches Valence Labs At Icml With A Commitment To Open Science Including 1 Million In Academic Scholarships
Recursion Launches Valence Labs At Icml With A Commitment To Open Science Including 1 Million In Academic Scholarships
Read more →RXRX▲ +78.2%on this news
Recursion Announces Collaboration And 50 Million Investment From Nvidia To Accelerate Groundbreaking Foundation Models In Ai Enabled Drug Discovery
Recursion Announces Collaboration And 50 Million Investment From Nvidia To Accelerate Groundbreaking Foundation Models In Ai Enabled Drug Discovery
Read more →RXRX▲ +78.2%on this news
experimental scale - up to millions of wet lab experiments weekly - and massive computational scale - owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, a
Recursion has announced a collaboration with NVIDIA, including a $50 million investment aimed at advancing AI-enabled drug discovery. This partnership will combine Recursion's extensive biological datasets with NVIDIA's computational capabilities. They plan to develop groundbreaking foundation models to speed up treatments for patients in the biotech and pharmaceutical sectors. Despite the optimistic developments, the collaboration faces inherent risks associated with pharmaceutical R&D and regulatory approvals.
Read more →RXRXRecursion Celebrates Opening Of Its Canadian Headquarters In Toronto With Government Officials And The Biotech Ecosystem
Recursion Celebrates Opening Of Its Canadian Headquarters In Toronto With Government Officials And The Biotech Ecosystem
Read more →RXRXRecursion S Phase 2 Trial For The Treatment Of Cerebral Cavernous Malformation Has Fully Enrolled
Recursion S Phase 2 Trial For The Treatment Of Cerebral Cavernous Malformation Has Fully Enrolled
Read more →RXRXjune2023deck Early June 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation R
Recursion has provided an update that includes a presentation outlining forward-looking statements related to its ongoing research and development efforts. They are advancing multiple clinical trials and making strategic acquisitions aimed at enhancing their drug discovery processes. Key highlights include a focus on oncology programs and the integration of advanced data solutions. However, the presentation highlights significant uncertainties and risks that could impact anticipated outcomes.
Read more →RXRXAltitude Lab Relocates To Gateway S Biohive Hub
Altitude Lab Relocates To Gateway S Biohive Hub
Read more →RXRX▼ -8.4%on this news
Recursion Appoints David Mauro M D Ph D As Chief Medical Officer
Recursion Appoints David Mauro M D Ph D As Chief Medical Officer
Read more →RXRX▲ +8.5%on this news
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further
Recursion (NASDAQ: RXRX) has reported its first-quarter financial results for 2023 and announced strategic agreements to acquire Cyclica and Valence, enhancing its digital chemistry and AI capabilities. The company has made significant progress in its clinical trial pipeline, with four trials ongoing, including REC-994 for Cerebral Cavernous Malformation. Recursion expects to integrate the teams from Cyclica and Valence into its operations and anticipates no material impact on its cash runway due to these acquisitions, expected to finalize in Q2 2023.
Read more →RXRX▲ +8.5%on this news
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities SALT LAKE CITY, TORONTO MONTR AL (
Recursion (NASDAQ: RXRX) has announced agreements to acquire Cyclica and Valence, two companies specializing in AI-enabled drug discovery, for $40 million and $47.5 million, respectively. These acquisitions are expected to strengthen Recursion's position in the biopharma industry by integrating advanced digital chemistry and machine learning capabilities into its existing technology platform. Recursion anticipates that these strategic moves will significantly enhance its drug discovery pipeline and attract top-tier talent in ML and AI. The acquisitions are set to be completed in the second quarter of 2023, pending customary closing conditions.
Read more →RXRXRecursion Publishes Second Annual Environmental Social And Governance Report
Recursion Publishes Second Annual Environmental Social And Governance Report
Read more →RXRXRecursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clini
Recursion reported its fourth quarter and fiscal year 2022 financial results, highlighting the initiation of five clinical trials, including three Phase 2 programs. The company emphasized the successful continuation of collaborations with Roche-Genentech and Bayer. Significant achievements, such as the launch of the RXRX3 dataset, were noted, contributing to advancements in drug discovery. Financially, Recursion experienced substantial growth in revenue, reflecting positive outcomes from its strategic partnerships.
Read more →RXRXCommunity Leaders Unite To Provide Support And Resources For Thousands Of Utahns With Rare Diseases
Community Leaders Unite To Provide Support And Resources For Thousands Of Utahns With Rare Diseases
Read more →RXRXdownloaddayslides Breakfast (8:30 - 9:30 AM) Welcome Tina Larson, President & COO R. Martin Chavez PhD, Chairman State of Recursion Chris Gibson PhD, Co-Founder & CEO Recursion OS Imran Haque PhD, VP of Data Science Lina
Recursion held a Download Day event featuring executives and scientists discussing the company's progress and future plans. The agenda included presentations on financials, potential milestones, and advancements in clinical trials. Emphasis was placed on their proprietary datasets and machine learning capabilities in drug discovery. The event also addressed various therapeutic areas, including oncology, fibrosis, and neuroscience, highlighting partnerships with other companies like Bayer and Roche.
Read more →RXRXDECODING BIOLOGY TO RADICALLY IMPROVE LIVES RECURSION JP Morgan Healthcare Conference January 10th, 2023 DISCLAIMERS This presentation and any accompanying discussion and documents contain information that includes or is
Recursion presented at the JP Morgan Healthcare Conference on January 10, 2023, outlining its innovative approach to drug discovery through an extensive biological and chemical dataset. The company launched multiple clinical trials in 2022 and emphasizes the role of robotic automation in accelerating research. However, forward-looking statements raise concerns about the reliability of projections and the inherent risks in the industry. Despite this, Recursion's advancements in drug discovery technology highlight its potential for significant impact.
Read more →RXRXRecursion Provides Business Updates and Reports Third Quarter 2022 Financial Results Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficil
Read more →RXRXRecursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB SALT LAKE CITY, October 25, 2022 Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it h
Read more →RXRXRecursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiat
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 SALT LAKE CITY, September 13, 2022 Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation of two additio
Read more →RXRX▼ -6.5%on this news
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
Read more →RXRX▼ -6.8%on this news· ran to +27% by day 3
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results Actively enrolling participants in our Phase 2 3 clinical trial for the potential treatment of progressive NF2 -mutated meningiomas On
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results Actively enrolling participants in our Phase 2 3 clinical trial for the potential treatment of progressive NF2-mutated meningiomas On track to initiate our Phase 2 clinical trial for the poten
Read more →RXRX▼ -5.6%on this news
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Read more →RXRX▲ +10%on this news
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2 -Mutated Meningiomas at Children s Tumor Foundation NF Conference. If successful, REC-2282 could be the first approved treatment for NF2 -mutated
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children s Tumor Foundation NF SALT LAKE CITY, June 20, 2022 /PRNewswire/ Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decod
Read more →RXRXRecursion Provides Business Updates and Reports First Quarter 2022 Financial Results Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first part
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2 3 clinical trial for progressive NF
Read more →RXRX▲ +6.6%on this news
Recursion to Participate in Upcoming Investor Conference
Recursion to Participate in Upcoming Investor Conference
Read more →RXRXRecursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis CITY, Apr. 11, 2022 Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that
Read more →RXRXRecursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscie
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to a
Read more →RXRXRecursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation Recursion s small molecule is the first therapeutic candidate to be advanced to an industry-sponsored
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation SALT LAKE CITY, March 18, 2022 /PRNewswire/ Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biolog
Read more →RXRX▼ -9.7%on this news· ran to -34% by day 3
Recursion Provides Updated Guidance on Clinical Trial Starts
Recursion Provides Updated Guidance on Clinical Trial Starts SALT LAKE CITY, March 3, 2022 Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts: Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology
Read more →RXRXth January 10 , 2022 2 This presentation and any accompanying discussion or documents may contain information that includes or is based upon forward looking statements within the meaning of the Securities Litigation Refo
2 This presentation and any accompanying discussion or documents may contain information that includes or is based upon forward looking statements within the meaning of the Securities Litigation Reform Act of 1995. These forward looking statements are based on our current expect
Read more →RXRX▲ +12.1%on this news
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Co
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology The deal, worth several billion dollars, is
Read more →RXRXRecursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen Recursion s powerful inferential search capabiliti
Read more →RXRX▼ -17.7%on this news
Recursion Provides Business Updates and Reports Third Quarter 2021 Financials Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2 3
Recursion Provides Business Updates and Reports Third Quarter 2021 Financials Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2 3 trial in early 2022 Advanced REC-994, a potential treatme
Read more →RXRX▲ +8.2%on this news
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2 -Mutated Meningiomas
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas SALT LAKE CITY, October 7, 2021 Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across
Read more →RXRXRecursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Read more →RXRX▲ +7.7%on this news
This presentation and any accompanying discussion or documents may contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These
Decoding Biology To Radically Improve Lives End of Q2 2021 Exhibit 99.1 This presentation and any accompanying discussion or documents may contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act
Read more →RXRXRecursion Reports Second Quarter 2021 Financials and Provides Business Updates Expanded the total number of research and development programs from 37 to 48 Announced first internally-developed NCE is advancing to IND-ena
Recursion Reports Second Quarter 2021 Financials and Provides Business Updates Expanded the total number of research and development programs from 37 to 48 Announced first internally-developed NCE is advancing to IND-enabling studies Planning to expand operations to Canada, wi
Read more →RXRXRecursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD Therapeutics Advisory Board to help guide Recursion s growing clinical pipeline through development
Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD Therapeutics Advisory Board to help guide Recursion s growing clinical pipeline through development SALT LAKE CITY, July 13, 2021 Recursion (NASDAQ: RXRX), a clinical-stage biotechnology compan
Read more →RXRXAltitude Lab Launches Investor Coalition to Fund and Mentor Healthcare Startups in Utah
Altitude Lab Launches Investor Coalition to Fund and Mentor Healthcare Startups in Utah
Read more →RXRXRecursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis
Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis
Read more →RXRXRecursion Reports First Quarter 2021 Financials and Provides Business Updates Strengthened balance sheet with the completion of a successful IPO Purchased, built, and activated BioHive-1, reportedly the 58th most powerfu
Recursion Reports First Quarter 2021 Financials and Provides Business Updates Strengthened balance sheet with the completion of a successful IPO Purchased, built, and activated BioHive-1, reportedly the 58th most powerful supercomputer in the world, to accelerate our drug disco
Read more →RXRXRecursion Pharmaceuticals Announces Closing of Initial Public Offering
Recursion Pharmaceuticals Announces Closing of Initial Public Offering SALT LAKE CITY, April 21, 2021 Recursion Pharmaceuticals, Inc. ( Recursion or we ) announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, whi
Read more →RXRXRecursion Pharmaceuticals Announces Pricing of Initial Public Offering
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering
Read more →RXRXR. Martin Chavez Appointed Chairman of Recursion's Board of Directors
R. Martin Chavez Appointed Chairman of Recursion's Board of Directors
Read more →RXRXRecursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Read more →RXRXRecursion Pharmaceuticals Named One of Utah's 2018 Top Workplaces by The Salt Lake Tribune
Recursion Pharmaceuticals Named One of Utah's 2018 Top Workplaces by The Salt Lake Tribune
Read more →RXRXRecursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Read more →RXRXVeteran Biopharma Operations Leader Tina M. Larson to Join Recursion as Chief Operating Officer
Veteran Biopharma Operations Leader Tina M. Larson to Join Recursion as Chief Operating Officer
Read more →RXRXMedicinal Chemistry Leaders Drs. Phil Carpino and Mike Genin Form New Chemistry Team at Recursion Pharmaceuticals
Medicinal Chemistry Leaders Drs. Phil Carpino and Mike Genin Form New Chemistry Team at Recursion Pharmaceuticals
Read more →RXRXRecursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious Disease
Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious Disease
Read more →RXRXPharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Read more →RXRXDr. Chand Sishta to lead regulatory affairs for Recursion Pharmaceuticals
Dr. Chand Sishta to lead regulatory affairs for Recursion Pharmaceuticals
Read more →RXRXDeep Learning Luminary Yoshua Bengio Joins Recursion Pharmaceuticals as Key Advisor
Deep Learning Luminary Yoshua Bengio Joins Recursion Pharmaceuticals as Key Advisor
Read more →RXRXDr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance Discovery Platform
Dr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance Discovery Platform
Read more →Competitive Position
How RXRX ranks across every disease it competes inCompetitive Position is a premium feature
See how RXRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial